The Food and Drug administration (FDA) just recently approved Addyi  (flibanserin) for treatment of hypoactive sexual desire disorder (HSDD) in pre/menopausal women.  Women with HSDD usually have low sexual desire which may not only affect themselves, but also their partners.  Prior to Addyi, there were no FDA approaved treatement options for low sexual desire in women.


The FDA has recognized for some time the challenges involved in developing treatments for female sexual dysfunction. The FDA held a public Patient-Focused Drug Development meeting and scientific workshop on female sexual dysfunction last October, to solicit perspectives directly from patients about their condition and its impact on daily life, and to discuss the scientific challenges related to developing drugs to treat these disorders.


The approval from the FDA came after a randomized, double-blind, placebo/controlled phase 3 study, showing increased satisfying sexual events.


If you’re having symptoms that match HSDD, you should speak with your doctor before considering taking a “pill” to treat this, since there may be non-pharmacological options. Also, you should go over the side-effect and drug-interaction profile of this pill with your doctor before intiating it.

» Reference